Market Overview

UPDATE: Wedbush Securities Reiterates Outperform Rating, Raises PT on Synageva BioPharma Corp.

Share:
Related GEVA
16 Biotech Catalysts SunTrust Is Tracking
US Stock Futures Surge Ahead Of Economic Data

In a report published Wednesday, Wedbush Securities reiterated its Outperform rating on Synageva BioPharma Corp. (NASDAQ: GEVA), and raised its price target from $42.00 to $50.00.

Wedbush Securities noted, “In an abstract at AALSD, the company reported that in 3 of 7 subjects where MRI data were available, there was a reduction in liver fat fractions, indicating that, in addition to normalization of liver enzymes and lipids, patients could be seeing additional clinical benefit with SBC-102 treatment. We expect updates to these data as they become available at AALSD and LDN (Q1:13).”

Synageva BioPharma Corp. closed on Tuesday at $42.85.

Latest Ratings for GEVA

DateFirmActionFromTo
Mar 2015JP MorganDowngradesOverweightNeutral
Feb 2015CitigroupMaintainsNeutral
Oct 2014SunTrust Robinson HumphreyInitiates Coverage onBuy

View More Analyst Ratings for GEVA
View the Latest Analyst Ratings

Posted-In: Wedbush SecuritiesAnalyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (GEVA)

Around the Web, We're Loving...